Humacyte Inc (HUMA) concluded trading on Thursday at a closing price of $2.77, with 6.57 million shares of worth about $18.19 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -38.31% during that period and on May 29, 2025 the price saw a gain of about 5.32%. Currently the company’s common shares owned by public are about 155.12M shares, out of which, 125.75M shares are available for trading.
Stock saw a price change of 18.38% in past 5 days and over the past one month there was a price change of 93.71%. Year-to-date (YTD), HUMA shares are showing a performance of -45.15% which decreased to -61.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.15 but also hit the highest price of $9.97 during that period. The average intraday trading volume for Humacyte Inc shares is 4.55 million. The stock is currently trading 46.75% above its 20-day simple moving average (SMA20), while that difference is up 50.49% for SMA50 and it goes to -32.13% lower than SMA200.
Humacyte Inc (NASDAQ: HUMA) currently have 155.12M outstanding shares and institutions hold larger chunk of about 39.87% of that.
The stock has a current market capitalization of $429.68M and its 3Y-monthly beta is at 1.96. It has posted earnings per share of -$0.69 in the same period. It has Quick Ratio of 3.28 while making debt-to-equity ratio of 2.28. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HUMA, volatility over the week remained 3.73% while standing at 8.36% over the month.
Stock’s fiscal year EPS is expected to rise by 84.68% while it is estimated to decrease by -46.11% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on May 14, 2025 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by H.C. Wainwright stated Humacyte Inc (HUMA) stock as a Buy in their note to investors on December 20, 2024, suggesting a price target of $15 for the stock. On December 11, 2023, H.C. Wainwright Initiated their recommendations, while on August 14, 2023, Piper Sandler Upgrade their ratings for the stock with a price target of $3.50. Stock get an Overweight rating from Cantor Fitzgerald on June 22, 2023.
